Feed PRFX
PR

PainReform Ltd.

PRFX · NASDAQ

$0.86 -1.15% (-$0.01)
1M -16.50%
Market Cap $74.7K
P/E Ratio -
Div. Yield -
ROE 99.08%

Bulios Fair Price

$1.17

36.0% upside

Trenutna cena

$0.86

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica PRFX trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
2/9
Valuation
80 /100
Cheap
P/B 0.01x
P/S 2.93x
EV/EBITDA N/A
Growth
0 /100
Declining
Book val. growth 8.14%
Rev. growth 41.75%
FCF growth N/A
Profitability
0 /100
Weak
Net margin 33,000.00%
Op. margin 34,772.50%
FCF margin 27,162.70%
Quality
0 /100
Poor
ROE 99.08%
ROA 70.14%
Asset turnover 0.00x
Debt
96 /100
Low
Current ratio 1.78x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
50 /100
Moderate
EPS volatility 45.18%
Profitable years 0
Beta 1.04x

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o PRFX
Online

O podjetju

PainReform Ltd. (PRFX) is a biotechnology company focused on developing innovative therapeutics for pain management. Their main product is a local anesthetic-based medication called PRF-110, which is intended for the treatment of acute and chronic pain conditions. PainReform Ltd. focuses on leveraging its patented technologies to enhance the efficacy and durability of medicinal preparations, providing patients with effective and safe pain treatment options. The company also focuses on developing new drug formulations and therapeutic applications to improve the quality of life for patients suffering from various painful conditions. Shares of PainReform Ltd. (PRFX) could be suitable for investors who are tracking innovations in pain management and seeking investment opportunities in the biotechnology sector.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Efraim Cohen-Arazi

Employees

7

Headquarters

Tel Aviv

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.